However, the related drugs for BLK, such as Fostamatinib and Zanubrutinib, and for NEU1, such as Oseltamivir, Acetylsalicylic acid, and Celecoxib, are inhibitors of their targets, which may potentially increase the risk of SLE. Here, BLK is linked to systemic lupus erythematosus.